Table 2.
Treatment characteristics
| No. of patients | ||
|---|---|---|
| HDCT | ||
| Yes | 2 | 11.1% |
| No | 16 | 88.9% |
| Consolidation with anti-GD2 antibodies | ||
| Yes | 12 | 66.7% |
| No | 6 | 33.3% |
| MIBG therapy | ||
| Yes | 10a | 55.6% |
| No | 8 | 44.4% |
| Radiotherapy of metastasis, median (range) | ||
| Total dose (Gy) | 36 (20–45) | |
| No. of fractions | 20 (12–30) | |
| Dose per fraction (Gy) | 1.8 (1.5–2) | |
| No. of irradiated metastases per patient | 1 (1–3) | |
| Radiotherapy of the primary tumor | ||
| Yes | 2 | 11.1% |
| No | 16 | 88.9% |
HDCT high-dose chemotherapy, MIBG 131-I-meta-iodobenzylguanidine
aMedian time between MIBG therapy and radiotherapy 110 days (range 3–478)